Dapagliflozin & Empagliflozin: Safe Diabetes Treatments – Real Data
Here’s a breakdown of the key facts from the provided text, focusing on dapagliflozin and empagliflozin:
Key Findings & comparison:
Comparable Benefits: Both dapagliflozin and empagliflozin showed statistically similar cardiorenal benefits and safety profiles overall.
Caution with Empagliflozin & ACE/ARB Use: A potential increased risk of all-cause death was observed with empagliflozin in patients who had recently stopped taking ACE inhibitors (ACEI) or angiotensin receptor blockers (ARB). This suggests caution is needed when switching patients from these blood pressure medications to empagliflozin.
Similar Mechanisms: Both drugs work by helping the kidneys remove glucose from the body, lowering blood sugar levels.
What Each Drug Does (Benefits):
Dapagliflozin:
Lowers blood sugar.
Reduces the risk of hospitalization for heart failure, cardiovascular disease, and kidney disease.
Empagliflozin:
Lowers blood sugar.
Reduces the risk of cardiovascular disease in patients with T2D and heart/blood vessel disease.
Reduces the risk of cardiovascular death and hospitalization for heart failure. Lowers the risk of worsening kidney disease.
Study Details:
Real-World Data: The study analyzed electronic health records from multiple institutions to get a realistic view of how these medications perform in practice.
Patient Population: Included over 4695 patients (18+ years old) with Type 2 Diabetes (T2D) and a certain level of kidney function (eGFR ≥25 mL/min/1.73 m²).
Study Period: Data collected from January 2016 to August 2023.
Matched Pairs: Researchers created 1662 pairs of patients, one starting dapagliflozin and one starting empagliflozin, to compare outcomes.
Primary Outcome: The study tracked a combination of negative outcomes: significant kidney function decline, end-stage renal disease, heart failure hospitalization, and all-cause death. This occurred in 16.2% of patients in both groups.
Type 2 Diabetes (T2D) Information:
Complex Disease: T2D often requires a combination of lifestyle changes (diet, exercise) and medication.
Symptoms: Can include frequent urination, thirst, fatigue, blurry vision, slow-healing wounds, but can also be mild and go unnoticed.
* Prevention/Early Treatment: Crucial for reducing the risk of cardiovascular events and chronic kidney disease.
Sources (as cited in the text):
- (Study comparing dapagliflozin and empagliflozin)
- (American Diabetes Association information on T2D)
- (Information on dapagliflozin)
- (Information on empagliflozin)